Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension

Cardiovascular Therapeutics

Volumn 31, Issue 1, 2013, Pages 38-44

  Bourge, Robert C ^a   Tapson, Victor F ^b   Safdar, Zeenat ^c   Benza, Raymond L ^d   Channick, Richard N ^e   Rosenzweig, Erika B ^f   Shapiro, Shelley ^g   White, Richard James ^h   Mcswain, Christopher Shane ⁱ   Gotzkowsky, Stephen Karl ⁱ   Nelsen, Andrew C ⁱ   Rubin, Lewis J ^j  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Department of Orthopaedic Surgery   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ UNITED THERAPEUTICS CORPORATION   (United States)

^j UCSD MEDICAL CENTER   (United States)

more..

Author keywords

Iloprost; Inhaled; Pulmonary arterial hypertension; Quality of life; Treprostinil

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ILOPROST; TREPROSTINIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COUGHING; DEATH; DEMOGRAPHY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; HEADACHE; HEALTH STATUS; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; PRIORITY JOURNAL; PRODUCTIVE COUGH; PULMONARY HYPERTENSION; QUALITY OF LIFE; RHINOPHARYNGITIS; SIDE EFFECT; THORAX DISEASE; THROAT IRRITATION; UPPER RESPIRATORY TRACT INFECTION; WALKING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ARTERY; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84872339756     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12008     Document Type: Article

References (28)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-1619.
2. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S.
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
4. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
6. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-338.
7. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
8. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-1922.
9. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-607.
10. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
11. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10:1084-1092.
12. Actelion Pharmaceuticals Ltd.: Ventavis (Iloprost) inhalation soultion. United States Food and Drug Administration Drug Product Label. 2011.
13. United Therapeutics Corporation: Tyvaso (Treprostinil) inhalation solution. United States Food and Drug Administration Drug Product Label. 2011.
14. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103-115.
15. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12.
16. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44:209-214.
17. Olschewski H, Rose F, Schermuly R, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004;102:139-153.
18. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004;126:1452-1459.
19. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005;6:92.
20. Zlupko M, Harhay MO, Gallop R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008;102:1431-1438.
21. Tay EL, Papaphylactou M, Diller GP, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol 2011;149:372-376.
22. Meads DM, McKenna SP, Doughty N, et al. The responsiveness and validity of the CAMPHOR utility index. Eur Respir J 2008;32:1513-1519.
23. Lin HY, Cheng TT, Wang JH, et al. Etoricoxib improves pain, function and quality of life: Results of a real-world effectiveness trial. Int J Rheum Dis 2010;13:144-150.
24. Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: Associations with hypoglycaemia and weight gain. Diabetes Obes Metab 2009;11:1138-1144.
25. Sweileh WM, Ihbesheh MS, Jarar IS, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 2011;21:301-305.
26. McConnell J, Hobbs K, Elwing J, Pushkin R. RESPIRE Registry: Inhalation Times and Treatment Adherence of Iloprost Delivered at 10 μg/mL and 20 μg/mL Concentrations in Patients with Pulmonary Arterial Hypertension. PHA: 9th International PH Conference and Scientific Sessions. 2010.
27. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006;48:1433-1437.
28. McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 2008;48:19-25.